Lyell Immunopharma, Inc.
NASDAQ:LYEL
0.6063 (USD) • At close March 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 105.597 | 145.647 | 123.554 | 293.828 | 140.406 | 96.674 |
| Short Term Investments
| 264.93 | 400.576 | 516.598 | 320.966 | 472.213 | 339.375 |
| Cash and Short Term Investments
| 370.527 | 546.223 | 640.152 | 614.794 | 612.619 | 436.049 |
| Net Receivables
| 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 9.067 | 8.463 | 11.143 | 22.984 | 4.928 | 8.42 |
| Total Current Assets
| 379.594 | 554.686 | 651.295 | 626.286 | 617.547 | 440.259 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 72.939 | 142.317 | 166.265 | 166.639 | 124.055 | 43.705 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 19 | 48.507 | 115.041 | 330.532 | 163.443 | 68.983 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 19.326 | 4.519 | 4.96 | 3.949 | 3.235 | 2.684 |
| Total Non-Current Assets
| 111.265 | 195.343 | 286.266 | 501.12 | 290.733 | 115.372 |
| Total Assets
| 490.859 | 750.029 | 937.561 | 1,127.406 | 908.28 | 555.631 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 5.366 | 4.817 | 3.917 | 3.207 | 9.396 | 2.844 |
| Short Term Debt
| 0 | 6.273 | 4.534 | 1.169 | 3.617 | 0.344 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 0 | 21.869 | 4.988 | 6.095 | 4.511 |
| Other Current Liabilities
| 48.422 | 23.429 | 28.577 | 37.374 | 30.177 | 14.346 |
| Total Current Liabilities
| 53.788 | 34.519 | 37.028 | 46.738 | 49.285 | 22.045 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 50.994 | 56.894 | 126.336 | 133.3 | 50.957 | 27.125 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 79.665 | 89.066 | 98.406 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | -98.406 |
| Other Non-Current Liabilities
| 3.253 | 3.664 | -59.055 | -62.084 | 0.532 | 0 |
| Total Non-Current Liabilities
| 54.247 | 60.558 | 67.281 | 150.881 | 140.555 | 125.531 |
| Total Liabilities
| 108.035 | 95.077 | 104.309 | 197.619 | 189.84 | 147.576 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 1,127.406 | 1,010.968 | 519.163 |
| Common Stock
| 0.029 | 0.025 | 0.025 | 0.024 | 0.002 | 0.001 |
| Retained Earnings
| -1,345.106 | -1,002.112 | -767.48 | -584.362 | -334.143 | -129.671 |
| Accumulated Other Comprehensive Income/Loss
| 0.291 | -0.094 | -7.599 | -1.623 | 0.256 | 0.454 |
| Other Total Stockholders Equity
| 1,727.61 | 1,657.133 | 1,608.306 | 1,515.748 | 41.357 | 18.108 |
| Total Shareholders Equity
| 382.824 | 654.952 | 833.252 | 929.787 | 718.44 | 408.055 |
| Total Equity
| 382.824 | 654.952 | 833.252 | 929.787 | 718.44 | 408.055 |
| Total Liabilities & Shareholders Equity
| 490.859 | 750.029 | 937.561 | 1,127.406 | 908.28 | 555.631 |